Intellia Therapeutics Schedules Phase 3 Topline Data Release for CRISPR Gene Editing Therapy in Hereditary Angioedema

What's happening

Intellia Therapeutics announced on April 24, 2026, that it will release topline data from its global Phase 3 HAELO clinical trial on April 27, 2026. The trial evaluates lonvoguran ziclumeran (lonvo-z), an investigational in vivo CRISPR-based gene editing therapy for hereditary angioedema. The company will host a webcast at 8:00 a.m. ET on April 27 to discuss the results.

This data release represents the first Phase 3 readout for an in vivo CRISPR-based gene editing candidate, positioning Intellia at the forefront of commercializing CRISPR technology for rare disease treatment. The company operates as a clinical-stage biotech with 377 employees and $67.7 million in revenue, focusing on CRISPR/Cas9-based gene editing therapies.

Why it matters for markets

The April 27 data release carries significant financial implications for Intellia's $1.61 billion market capitalization, with the stock trading at $13.63 after declining 14.11% recently. The company's shares have fluctuated between $6.83 and $28.25 over the past 52 weeks, indicating high volatility around clinical milestones. As the first Phase 3 in vivo CRISPR readout, positive results could validate the entire gene editing sector's commercial potential.

Intelliahas two Phase 3 programs running simultaneously, with NTLA-2001 for transthyretin amyloidosis also in late-stage development alongside the hereditary angioedema program. The company's modular platform approach and partnerships with Regeneron provide additional revenue opportunities beyond the immediate trial results. Given Intellia's $67.7 million revenue base, successful Phase 3 data could significantly expand the company's commercial prospects in the rare disease market.

Sectors and assets to watch

The gene editing and biotechnology sectors face a pivotal moment with Intellia's Phase 3 readout, particularly companies developing CRISPR-based therapies. Intellia Therapeutics (NTLA) represents the primary investment vehicle for in vivo CRISPR exposure, with its current $13.63 share price reflecting market uncertainty ahead of the data release. The broader rare disease treatment sector could see renewed investor interest if the hereditary angioedema results demonstrate commercial viability.

Companies with CRISPR partnerships or competing gene editing platforms may experience secondary effects from Intellia's results. The outcome could influence investor sentiment toward other clinical-stage biotechnology companies pursuing gene editing approaches for rare diseases, particularly those with similar in vivo delivery mechanisms.

What to watch next

Monitor Intellia's April 27, 2026, webcast at 8:00 a.m. ET for detailed efficacy and safety data from the Phase 3 HAELO trial. Key metrics will include the primary endpoint results, patient response rates, and any safety signals that could impact regulatory approval prospects. The market reaction to these results will likely influence the broader gene editing sector and provide insight into investor appetite for CRISPR commercialization timelines.